Surrozen (SRZN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Scientific and clinical focus

• Emphasis on Wnt pathway biology and antibody engineering, targeting retinal vascular diseases such as diabetic macular edema (DME) and wet AMD.

• Wnt pathway activation restores normal vessel architecture and function, offering a disease-modifying approach distinct from VEGF inhibition.

• Experimental data show Wnt activation increases tight junction proteins, reducing retinal leakage.

• Clinical outcomes can be measured by standard imaging (OCT, OCTA), with rapid effects seen within weeks.

• Mouse models indicate potential for revascularization in areas where VEGF therapies are ineffective.

Competitive landscape and pipeline

• Current market dominated by Vabysmo (Roche) and Eylea, with smaller roles for Lucentis and Avastin.

• In Wnt biology, main competitors are Merck (Restoret/MK-3000) and Roche, with Surrozen positioned as a key innovator.

• Surrozen's lead molecule (8141) combines Wnt activation and VEGF inhibition, aiming for superior potency and clinical outcomes.

• 8143, months behind 8141, adds IL-6 inhibition for broader application in inflammatory-driven macular edemas.

• Partnership with Boehringer Ingelheim (SZN-413) has yielded $22.5M, with clinical entry pending.

Development timelines and expectations

• IND for 8141 expected in 2026, with trial design and data expectations to be detailed soon.

• 8143 is a trifunctional molecule, positioned for UME and inflammatory macular edemas, with timeline updates forthcoming.

• Merck’s phase III data (Restoret) expected in September and March, with outcomes likely to influence the field and validate the multi-target approach.

• Clinical endpoints focus on best-corrected visual acuity and retinal drying/fluid reduction.